AR017201A1 - Forma de dosificacion farmaceutica entericamente recubierta de liberacion prolongada de un inhibidor de h+, k+ -atpasa, procedimiento para su manufactura,uso de la forma de dosificacion farmaceutica y uso del inhibidor para preparar un medicamento - Google Patents

Forma de dosificacion farmaceutica entericamente recubierta de liberacion prolongada de un inhibidor de h+, k+ -atpasa, procedimiento para su manufactura,uso de la forma de dosificacion farmaceutica y uso del inhibidor para preparar un medicamento

Info

Publication number
AR017201A1
AR017201A1 ARP980106244A ARP980106244A AR017201A1 AR 017201 A1 AR017201 A1 AR 017201A1 AR P980106244 A ARP980106244 A AR P980106244A AR P980106244 A ARP980106244 A AR P980106244A AR 017201 A1 AR017201 A1 AR 017201A1
Authority
AR
Argentina
Prior art keywords
inhibitor
hydrogen
same
dosage form
pharmaceutical dosage
Prior art date
Application number
ARP980106244A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR017201A1 publication Critical patent/AR017201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una forma de dosificacion farmacéutica de liberacion prolongada de recubrimiento entérico de un inhibidor de H+,K+ -ATPasa que proporciona un perfil deconcentracion de plasma prolongado de un inhibidor de H+,K+-ATPasa. El perfil prolongado en el plasma se obtiene mediante una composicicion farmacéutica quecomprende un material de nucleo de una matriz hidrofílica o hidrofobica, y el inhibidor de H+,K+ -ATPasa y opcionalmente excipientes farmacéuticamenteaceptables. El inhibidor de H+,K+ -ATPasa es un compuesto de formula (I), donde Het1 es formula (II); Het2 es formula (III); X= es formula (IV), donde N en laporcion benzimidazol significa que uno de los átomos de carbono del anillo sustituido por R6-R9 puede estar opcionalmente intercambiadopor un átomo denitrogeno sin ningun sustituyente; R1 R2 y R3 son iguales o diferentes y están seleccionados de hidrogeno, alquilo, alcoxi, opcionalmente sustituido por fluor,alquiltio, alcoxialcoxi, dialquilamino, piperidino, morfolino, halogeno, fenilo y fenilalcoxi; R4 y R5 son iguales o diferentes y están seleccionados dehidrogeno, alquilo y arilalquilo; R6 es hidrogeno, halogeno, trifluormetilo, alquilo o alcoxi; R6 y R9 son iguales o diferentes y están seleccionados dehidrogeno, alcoxi, halogeno, haloalcoxi, alquilcarbonil, alcoxicarbonilo, oxazolinilo y trifluoralquilo, o los grupos adyacentes R6-R9 forman estructuras deanillo que pueden ser adicionalmente sustituidas; R10 es hidrogeno o forma una cadena alquileno conjuntamente con R3 y R11 y R12 son iguales o diferentes yestán seleccionados de hidrogeno, halogeno o alquilo; o una sal alcalina de la misma, uno de los enantiomeros de la misma o una sal alcalina de uno de losenantiomeros. Preferiblemente el inhibidor de H+,K+ -ATPasa está seleccionado del grupo omeprazol, una sal alcalina de omeprazol, el (-) enantiomero deomeprazol o una sal alcalina del(-) enantiomero de omeprazol o del grupo que comprende lanzoprazol, pantoprazol, sales alcalinas del mismo, un enantiomerodelmismo o una sal alcalina del mismo. La matriz hidrofílica es un polímero hidrofílico usado solo o una mezcla de polímeros hidrofílicos. La matriz hidrofílica
ARP980106244A 1997-12-22 1998-12-09 Forma de dosificacion farmaceutica entericamente recubierta de liberacion prolongada de un inhibidor de h+, k+ -atpasa, procedimiento para su manufactura,uso de la forma de dosificacion farmaceutica y uso del inhibidor para preparar un medicamento AR017201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704869A SE9704869D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulaton II

Publications (1)

Publication Number Publication Date
AR017201A1 true AR017201A1 (es) 2001-08-22

Family

ID=20409571

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980106244A AR017201A1 (es) 1997-12-22 1998-12-09 Forma de dosificacion farmaceutica entericamente recubierta de liberacion prolongada de un inhibidor de h+, k+ -atpasa, procedimiento para su manufactura,uso de la forma de dosificacion farmaceutica y uso del inhibidor para preparar un medicamento

Country Status (39)

Country Link
US (1) US6605303B1 (es)
EP (1) EP1043976B1 (es)
JP (1) JP4865945B2 (es)
KR (2) KR20060097069A (es)
CN (1) CN1171582C (es)
AR (1) AR017201A1 (es)
AT (1) ATE312602T1 (es)
AU (1) AU759634B2 (es)
BG (1) BG65028B1 (es)
BR (1) BR9814378A (es)
CA (1) CA2315261C (es)
CY (1) CY1106072T1 (es)
CZ (1) CZ299228B6 (es)
DE (1) DE69832816T2 (es)
DK (1) DK1043976T3 (es)
DZ (1) DZ2685A1 (es)
EE (1) EE04901B1 (es)
ES (1) ES2252875T3 (es)
HK (1) HK1034455A1 (es)
HR (1) HRP20000380B1 (es)
HU (1) HUP0101437A3 (es)
IL (2) IL136827A0 (es)
IS (1) IS5524A (es)
MA (1) MA26576A1 (es)
MY (1) MY126555A (es)
NO (1) NO20003218L (es)
NZ (1) NZ505127A (es)
PL (1) PL193776B1 (es)
RU (1) RU2214232C2 (es)
SA (1) SA99191077B1 (es)
SE (1) SE9704869D0 (es)
SK (1) SK284988B6 (es)
TN (1) TNSN98229A1 (es)
TR (1) TR200001981T2 (es)
TW (1) TWI249410B (es)
UA (1) UA69397C2 (es)
WO (1) WO1999032091A1 (es)
YU (1) YU36700A (es)
ZA (1) ZA9811239B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL186605B1 (pl) * 1995-09-21 2004-01-30 Pharma Pass Llc Tabletka lub mikrotabletka zawierająca rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol oraz sposób wytwarzania tabletek lub mikrotabletek zawierających rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
WO1999029320A1 (en) 1997-12-08 1999-06-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel administration form comprising an acid-labile active compound
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
CN100335040C (zh) * 2000-12-07 2007-09-05 奥坦纳医药公司 含有酸敏感型活性成分的快速崩解片剂
JP4848101B2 (ja) * 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション 徐放性マイクロペレット
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
KR20050065550A (ko) 2002-09-26 2005-06-29 아스텔라스세이야쿠 가부시키가이샤 약물 흡수성 개선제
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
JP4493970B2 (ja) * 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
EP1607088B1 (en) 2003-03-17 2019-02-27 Takeda Pharmaceutical Company Limited Controlled release composition
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
WO2005012289A1 (en) * 2003-07-17 2005-02-10 Altana Pharma Ag Novel salt of (r) - pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
FR2861990B1 (fr) * 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
EP1768668A2 (en) * 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
WO2006082523A2 (en) * 2005-01-25 2006-08-10 Aurobindo Pharma Limited Pharmaceutical sustained release composition of metformin
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
DE102005060393A1 (de) * 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Orales Präparat mit kontrollierter Freisetzung
SG184754A1 (en) * 2005-12-28 2012-10-30 Takeda Pharmaceutical Controlled release solid preparation
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
WO2008094877A2 (en) * 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
WO2008112388A1 (en) * 2007-03-14 2008-09-18 Drugtech Corporation Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
US8173158B2 (en) * 2007-10-12 2012-05-08 Takeda Pharmaceuticals U.S.A., Inc. Methods of treating gastrointestinal disorders independent of the intake of food
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
WO2010103365A2 (en) 2009-03-09 2010-09-16 Council Of Scientific & Industrial Research Sustained release composition of therapeutic agent
US20140127296A1 (en) * 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
MX368536B (es) 2013-02-13 2019-10-07 Redhill Biopharma Ltd Composicion farmaceutica para el tratamiento de helicobacter pylori.
CN104721185A (zh) * 2013-12-21 2015-06-24 辰欣药业股份有限公司 一种提高埃索美拉唑钠稳定性的方法
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
US5229181A (en) * 1990-10-30 1993-07-20 Amber Technologies Tubular knit cleanroom wiper
TW209174B (es) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
DK0661045T3 (da) * 1992-09-18 2002-10-28 Yamanouchi Pharma Co Ltd Hydrogelpræparat med forsinket frigivelse
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
JPH07330629A (ja) * 1994-06-02 1995-12-19 Nippon Shokubai Co Ltd 徐放性製剤
ATE414509T1 (de) * 1994-07-08 2008-12-15 Astrazeneca Ab Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform
BR9508261A (pt) * 1994-07-08 1997-12-23 Astra Ab Formulação oral entericamente revestida uso da mesma processo para preparer a formulação inibir a secreção de ácido gástrico em mamíferos e no ser humano e tratar doenças relacionadas ao ácido gástrico em maníferos e no ser humano e pacote de empola de pressão transversal
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
WO1997047285A1 (en) * 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US7016717B2 (en) * 2002-07-05 2006-03-21 The Regents Of The University Of California Near-infrared spectroscopic tissue imaging for medical applications
ITPD20050230A1 (it) * 2005-07-28 2007-01-29 Marcato Spa Macchina ad uso domestico per la estrusione di paste alimentari fresche

Also Published As

Publication number Publication date
IL136827A (en) 2007-05-15
AU759634B2 (en) 2003-04-17
JP2001526211A (ja) 2001-12-18
SE9704869D0 (sv) 1997-12-22
CZ20002314A3 (cs) 2000-11-15
EE200000383A (et) 2001-12-17
NO20003218D0 (no) 2000-06-21
BG65028B1 (bg) 2006-12-29
SA99191077B1 (ar) 2006-07-11
CN1171582C (zh) 2004-10-20
WO1999032091A1 (en) 1999-07-01
BR9814378A (pt) 2000-10-10
AU1991299A (en) 1999-07-12
ATE312602T1 (de) 2005-12-15
SK284988B6 (sk) 2006-04-06
YU36700A (sh) 2003-01-31
EP1043976B1 (en) 2005-12-14
HUP0101437A3 (en) 2003-01-28
CY1106072T1 (el) 2011-06-08
TNSN98229A1 (fr) 2005-03-15
SK8072000A3 (en) 2001-01-18
HRP20000380B1 (en) 2007-08-31
DE69832816T2 (de) 2006-08-31
HRP20000380A2 (en) 2001-06-30
IS5524A (is) 2000-06-08
BG104620A (en) 2001-04-30
US6605303B1 (en) 2003-08-12
DE69832816D1 (de) 2006-01-19
UA69397C2 (uk) 2004-09-15
PL193776B1 (pl) 2007-03-30
MA26576A1 (fr) 2004-12-20
CN1284866A (zh) 2001-02-21
KR20010033428A (ko) 2001-04-25
CA2315261A1 (en) 1999-07-01
HK1034455A1 (en) 2001-10-26
EP1043976A1 (en) 2000-10-18
NZ505127A (en) 2003-02-28
TR200001981T2 (tr) 2000-11-21
KR100755154B1 (ko) 2007-09-04
KR20060097069A (ko) 2006-09-13
PL341428A1 (en) 2001-04-09
ZA9811239B (en) 1999-06-22
JP4865945B2 (ja) 2012-02-01
CZ299228B6 (cs) 2008-05-21
HUP0101437A2 (hu) 2001-10-28
IL136827A0 (en) 2001-06-14
NO20003218L (no) 2000-08-22
EE04901B1 (et) 2007-10-15
DK1043976T3 (da) 2006-03-20
DZ2685A1 (fr) 2003-03-29
ES2252875T3 (es) 2006-05-16
RU2214232C2 (ru) 2003-10-20
TWI249410B (en) 2006-02-21
CA2315261C (en) 2008-02-12
MY126555A (en) 2006-10-31

Similar Documents

Publication Publication Date Title
AR017201A1 (es) Forma de dosificacion farmaceutica entericamente recubierta de liberacion prolongada de un inhibidor de h+, k+ -atpasa, procedimiento para su manufactura,uso de la forma de dosificacion farmaceutica y uso del inhibidor para preparar un medicamento
AR017202A1 (es) Forma de dosificacion farmaceutica oral de liberacion pulsada y procedimiento para la preparacion de la misma y su uso para la manufactura de unmedicamento
AR008750A1 (es) Formas de dosis farmaceuticas orales que comprende un inhibidor de bombeo protonico y un agente procinetico, proceso para su fabricacion y uso de dichasformas para la fabricacion de medicamentos
RU2000116011A (ru) Пероральная фармацевтическая лекарственная форма с продолжительным высвобождением
AR012593A1 (es) Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento
JP2003063994A (ja) アルツハイマー病およびパーキンソン病に関連する痴呆または認識障害のための組合せ治療
RU96120189A (ru) Новые фармацевтические препараты и способы их получения
JP2003500442A5 (es)
YU46421B (sh) Postupak za dobijanje farmaceutskog preparata kiselinski labilnih supstanci za oralnu upotrebu
RU2001135826A (ru) Новое применение соединений в качестве антибактериальных средств
AR041262A1 (es) Metodos para tratar los trastornos de ojo seco
AR030676A1 (es) Derivados de aminas y amidas como ligandos para el receptor del neuropeptido y y5 utiles en el tratamiento de la obesidad y otros trastornos, uso de los mismos para la elaboracion de medicamentos y composiciones farmaceuticas que los comprenden
CA2170644A1 (en) Multiple unit pharmaceutical preparation containing proton pump inhibitor
RU96107040A (ru) Многоединичный фармацевтический препарат, содержащий ингибитор протонного насоса
AR100473A2 (es) Un método para la manufactura de una preparación para administración oral
AR067965A2 (es) Compuestos que contienen lactama inhibidores del factor x de coagulacion, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos tromboenmbolicos.
RU2007101309A (ru) Боросодержащее соединение и способы применения
FI20001864A (fi) 2-(2,6-dioksopiperidiini-3-yyli)isoindoliini johdannaiset niiden valmistus ja käyttö inflammatoristen sytokiinien estäjinä
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20001600A1 (es) Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica
RU2009131454A (ru) Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств
RS49590B (sr) Upotreba inhibitora h+,k+-atpaze za proizvodnju novih farmaceutskih preparata
RU99101081A (ru) Режим введения ингибиторов н+, к+-атфазы
CA2425199A1 (en) Formulation of substituted benzimidazoles

Legal Events

Date Code Title Description
FA Abandonment or withdrawal